Vitamin D receptors from patients with resistance to 1,25- dihydroxyvitamin D3: Point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner

G Kerr Whitfield, Sanford H. Selznick, Carol A. Haussler, Jui-Cheng Hsieh, Michael A. Galligan, Peter W. Jurutka, Paul D. Thompson, Stanley M. Lee, Joseph E. Zerwekh, Mark R Haussler

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Hereditary hypocalcemic vitamin D-resistant rickets is attributable to defects in the nuclear receptor for 1,25-dihydroxyvitamin D3 [1,25- (OH)2D3]. Two novel point mutations (I314S and R391C) identified in the hormone-binding domain of the human vitamin D receptor (VDR) from patients with hereditary hypocalcemic vitamin D-resistant rickets confer the receptor with sharply reduced 1,25-(OH)2D3-dependent transactivation. These natural mutations, especially R391C, also lead to a second specific consequence, namely impaired heterodimeric interaction with retinoid X receptor (RXR). While the transactivation ability of the I314S mutant can be largely restored by providing excess 1,25(OH)2D3, R391C activity is more effectively restored with exogenous RXR. These observations are reflected also in the clinical course of each patient: the patient bearing the I314S mutation showed a nearly complete cure with pharmacological doses of a vitamin D derivative, whereas the patient bearing R391C responded only partially to such therapy. Further tests with patient fibroblasts and transfected cells show that the activity of the I314S VDR mutant is augmented somewhat by added RXR, while transactivation by the R391C mutant is best corrected by RXR in the presence of excess hormone. Thus, the effects of hormone vs. RXR in bolstering these mutant VDRs, such that they mediate efficient transactivation, are not entirely separable. The unique properties of these genetically altered receptors establish a new subclass of natural human VDR mutants that illustrate, in vivo, the importance of both 1,25-(OH)2D3 binding and heterodimerization with RXR in VDR action.

Original languageEnglish (US)
Pages (from-to)1617-1631
Number of pages15
JournalMolecular Endocrinology
Volume10
Issue number12
DOIs
StatePublished - 1996

Fingerprint

Retinoid X Receptors
Calcitriol Receptors
Calcitriol
Point Mutation
Transcriptional Activation
Ligands
Hypophosphatemic Rickets
Hormones
Mutation
Cytoplasmic and Nuclear Receptors
Vitamin D
Fibroblasts
Pharmacology

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology, Diabetes and Metabolism

Cite this

Vitamin D receptors from patients with resistance to 1,25- dihydroxyvitamin D3 : Point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner. / Whitfield, G Kerr; Selznick, Sanford H.; Haussler, Carol A.; Hsieh, Jui-Cheng; Galligan, Michael A.; Jurutka, Peter W.; Thompson, Paul D.; Lee, Stanley M.; Zerwekh, Joseph E.; Haussler, Mark R.

In: Molecular Endocrinology, Vol. 10, No. 12, 1996, p. 1617-1631.

Research output: Contribution to journalArticle

@article{25599296e6714b3fa8e92ac5131f8dcc,
title = "Vitamin D receptors from patients with resistance to 1,25- dihydroxyvitamin D3: Point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner",
abstract = "Hereditary hypocalcemic vitamin D-resistant rickets is attributable to defects in the nuclear receptor for 1,25-dihydroxyvitamin D3 [1,25- (OH)2D3]. Two novel point mutations (I314S and R391C) identified in the hormone-binding domain of the human vitamin D receptor (VDR) from patients with hereditary hypocalcemic vitamin D-resistant rickets confer the receptor with sharply reduced 1,25-(OH)2D3-dependent transactivation. These natural mutations, especially R391C, also lead to a second specific consequence, namely impaired heterodimeric interaction with retinoid X receptor (RXR). While the transactivation ability of the I314S mutant can be largely restored by providing excess 1,25(OH)2D3, R391C activity is more effectively restored with exogenous RXR. These observations are reflected also in the clinical course of each patient: the patient bearing the I314S mutation showed a nearly complete cure with pharmacological doses of a vitamin D derivative, whereas the patient bearing R391C responded only partially to such therapy. Further tests with patient fibroblasts and transfected cells show that the activity of the I314S VDR mutant is augmented somewhat by added RXR, while transactivation by the R391C mutant is best corrected by RXR in the presence of excess hormone. Thus, the effects of hormone vs. RXR in bolstering these mutant VDRs, such that they mediate efficient transactivation, are not entirely separable. The unique properties of these genetically altered receptors establish a new subclass of natural human VDR mutants that illustrate, in vivo, the importance of both 1,25-(OH)2D3 binding and heterodimerization with RXR in VDR action.",
author = "Whitfield, {G Kerr} and Selznick, {Sanford H.} and Haussler, {Carol A.} and Jui-Cheng Hsieh and Galligan, {Michael A.} and Jurutka, {Peter W.} and Thompson, {Paul D.} and Lee, {Stanley M.} and Zerwekh, {Joseph E.} and Haussler, {Mark R}",
year = "1996",
doi = "10.1210/me.10.12.1617",
language = "English (US)",
volume = "10",
pages = "1617--1631",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - Vitamin D receptors from patients with resistance to 1,25- dihydroxyvitamin D3

T2 - Point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner

AU - Whitfield, G Kerr

AU - Selznick, Sanford H.

AU - Haussler, Carol A.

AU - Hsieh, Jui-Cheng

AU - Galligan, Michael A.

AU - Jurutka, Peter W.

AU - Thompson, Paul D.

AU - Lee, Stanley M.

AU - Zerwekh, Joseph E.

AU - Haussler, Mark R

PY - 1996

Y1 - 1996

N2 - Hereditary hypocalcemic vitamin D-resistant rickets is attributable to defects in the nuclear receptor for 1,25-dihydroxyvitamin D3 [1,25- (OH)2D3]. Two novel point mutations (I314S and R391C) identified in the hormone-binding domain of the human vitamin D receptor (VDR) from patients with hereditary hypocalcemic vitamin D-resistant rickets confer the receptor with sharply reduced 1,25-(OH)2D3-dependent transactivation. These natural mutations, especially R391C, also lead to a second specific consequence, namely impaired heterodimeric interaction with retinoid X receptor (RXR). While the transactivation ability of the I314S mutant can be largely restored by providing excess 1,25(OH)2D3, R391C activity is more effectively restored with exogenous RXR. These observations are reflected also in the clinical course of each patient: the patient bearing the I314S mutation showed a nearly complete cure with pharmacological doses of a vitamin D derivative, whereas the patient bearing R391C responded only partially to such therapy. Further tests with patient fibroblasts and transfected cells show that the activity of the I314S VDR mutant is augmented somewhat by added RXR, while transactivation by the R391C mutant is best corrected by RXR in the presence of excess hormone. Thus, the effects of hormone vs. RXR in bolstering these mutant VDRs, such that they mediate efficient transactivation, are not entirely separable. The unique properties of these genetically altered receptors establish a new subclass of natural human VDR mutants that illustrate, in vivo, the importance of both 1,25-(OH)2D3 binding and heterodimerization with RXR in VDR action.

AB - Hereditary hypocalcemic vitamin D-resistant rickets is attributable to defects in the nuclear receptor for 1,25-dihydroxyvitamin D3 [1,25- (OH)2D3]. Two novel point mutations (I314S and R391C) identified in the hormone-binding domain of the human vitamin D receptor (VDR) from patients with hereditary hypocalcemic vitamin D-resistant rickets confer the receptor with sharply reduced 1,25-(OH)2D3-dependent transactivation. These natural mutations, especially R391C, also lead to a second specific consequence, namely impaired heterodimeric interaction with retinoid X receptor (RXR). While the transactivation ability of the I314S mutant can be largely restored by providing excess 1,25(OH)2D3, R391C activity is more effectively restored with exogenous RXR. These observations are reflected also in the clinical course of each patient: the patient bearing the I314S mutation showed a nearly complete cure with pharmacological doses of a vitamin D derivative, whereas the patient bearing R391C responded only partially to such therapy. Further tests with patient fibroblasts and transfected cells show that the activity of the I314S VDR mutant is augmented somewhat by added RXR, while transactivation by the R391C mutant is best corrected by RXR in the presence of excess hormone. Thus, the effects of hormone vs. RXR in bolstering these mutant VDRs, such that they mediate efficient transactivation, are not entirely separable. The unique properties of these genetically altered receptors establish a new subclass of natural human VDR mutants that illustrate, in vivo, the importance of both 1,25-(OH)2D3 binding and heterodimerization with RXR in VDR action.

UR - http://www.scopus.com/inward/record.url?scp=10544241193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10544241193&partnerID=8YFLogxK

U2 - 10.1210/me.10.12.1617

DO - 10.1210/me.10.12.1617

M3 - Article

C2 - 8961271

AN - SCOPUS:10544241193

VL - 10

SP - 1617

EP - 1631

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 12

ER -